The Pharmacovigilance Processing Crisis
Drug safety teams drown in case volume while regulatory clocks tick. Manual ICSR processing is slow, inconsistent, and increasingly unsustainable as product portfolios grow.
Common challenges in icsr & adverse event processing include high operational costs, slow processing times, manual errors, and scalability limitations. Traditional approaches to icsr & adverse event processing struggle with exponential growth in icsr volume from digital channels, literature and patient communities, leading to inefficiencies and missed opportunities. Organizations face increasing pressure to modernize icsr & adverse event processingoperations while maintaining compliance and reducing costs.
- Exponential growth in ICSR volume from digital channels, literature and patient communities
- Manual MedDRA coding is inconsistent across different coders and geographies
- 15-day and 7-day expedited reporting deadlines create constant operational pressure
- High cost of maintaining global PV teams proportional to product portfolio size